Eisai and Biogen launch Alzheimer's drug Leqembi in China
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 28 2024
0mins
Source: reuters
- Eisai and Biogen Launch Alzheimer's Treatment in China: They have introduced their Alzheimer's treatment, Leqembi, in China after the U.S. and Japan, offering a drug that removes beta amyloid protein from the brain.
- Leqembi Pricing and Coverage: The drug will be priced at 2,508 yuan for a 200 mg vial in the private market, with plans for partial coverage by a major Chinese medical insurance firm.
- Regulatory Approvals: China approved the Alzheimer's treatment in January following standard approval from the U.S. FDA in July last year.
- Future Alzheimer's Blood Tests: More convenient blood tests for Alzheimer's expected by 2025 could help Eisai target a larger share of China's 17 million people with early-stage disease.
- Financial Information: The exchange rate is $1 to 7.2688 Chinese yuan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
